Hepatitis C Pricing and Reimbursement

Hepatitis C Pricing and Reimbursement

  • January 2015 •
  • 74 pages •
  • Report ID: 3384792 •
  • Format: PDF
The pricing and reimbursement of hepatitis C therapies has been in the spotlight since the launch of Sovaldi in the US in December 2013 at the price of $1,000 per pill. While Sovaldi's and Harvoni’s clinical effectiveness are undisputed, their high prices have prompted widespread criticism from payers, politicians, and patients due to the large budgetary impact of treating all eligible patients, which will exert a significant strain on healthcare systems.

This report addresses the following questions:
- What reimbursement restrictions have been imposed by US payers and how do they differ between major brands?
- Which payers have imposed patient prioritization and how do the strategies differ between countries?
- How are European payers controlling expenditure on hepatitis C drugs?
- In which markets did Sovaldi have the best outcome of the health technology assessment?

Loading...

We are very sorry, but an error occurred.
Please contact support@reportbuyer.com if the problem remains.